David Wofsy, MD
Professor
Medicine
School of Medicine
Dr. Wofsy received his undergraduate degree from Harvard (1968), his MD from the University of California, San Diego (1974), and his medical residency training and rheumatology fellowship training from the University of California, San Francisco. He joined the UCSF faculty in 1980. He currently Professor of Medicine and Microbiology/Immunology at UCSF.
Show full bio (280 words) Hide full bio
Dr. Wofsy also serves as Associate Dean for Admissions for the UCSF School of Medicine. He has served on numerous NIH study sections, and on the Arthritis Advisory Committee of the Food and Drug Administration. Dr. Wofsy is a past-President of the American College of Rheumatology.
Dr. Wofsy's research program is devoted to the development of novel therapies for autoimmune diseases, particularly systemic lupus erythematosus (SLE). For many years, his research focused on the cellular and molecular mechanisms that lead to autoimmunity in murine models for SLE. These therapies are designed to block pathologic immune responses without damaging the entire immune system. One of the therapies that was pioneered by Dr. Wofsy's group involves the B7 family of molecules on antigen-presenting cells (APC). These molecules play a pivotal role in the generation of T-cell help. Specifically, the interaction of B7 molecules on APC with their ligand (designated CD28) on T cells provides an important signal for T-cell activation. Dr. Wofsy first showed that selective inhibition of the B7-CD28 interaction retards autoimmunity in murine lupus. He subsequently showed that this beneficial effect could be enhanced substantially in two ways: (i) by combining blockade of B7-CD28 with blockade of other receptor-ligand pairs (CD40-CD40L) on the surface of T cells and APC; and (ii) by combining blockade of B7-CD28 with cyclophosphamide therapy. In each case, combination therapy provided a prolonged benefit without sustained generalized immune suppression. This work laid the foundation for translational studies that resulted in FDA approval of a new treatment for rheumatoid arthritis. Dr.Wofsy's current research is focused on establishing whether this therapy can be life-saving in people with kidney disease due to SLE.
Awards
Show all (5) Hide
- Master of the American College of Rheumatology, American College of Rheumatology, 2012
- Paul Klemperer Award and Medal, New York Academy of Medicine, 2011
- Lee C. Howley Sr. Prize, Arthritis Foundation, 2007
- Arthritis Hero Award, Arthritis Foundation, 2001
- Edmund L. Dubois Award for Outstanding Research in SLE, American College of Rheumatology, 1999
Education & Training
Show all (2) Hide
- Diversity, Equity, and Inclusion Champion Training University of California 2017
- Residency School of Medicine University of California, San Francisco
Websites
Show all (1) Hide
- Profile at UCSF Immunology Program (immunology.ucsf.edu)
Grants and Projects
Show all (8) Hide
- PEARL: Pathway Exploration and Analysis in Renal Lupus, NIH, 2014-2021
- Autoimmunity Center of Excellence Clinical Research Program, NIH, 2014-2020
- Academic Rheumatology and Clinical Immunology, NIH, 1978-2019
- Autoimmunity Center of Excellence, NIH, 2003-2015
- General Clinical Research Center, NIH, 1974-2009
- Multipurpose Arthritis and Musculoskeletal Diseases Ctr, NIH, 1977-2003
- New Strategies for Using Anti-l3T4 to Study Murine Lupus, NIH, 1988-1991
- U.c.s.f. Multipurpose Arthritis Center, NIH, 1977-1988
Publications (122)
Top publication keywords:
Immunosuppressive AgentsClinical Trials, Phase II as TopicRecombinant Fusion ProteinsImmunoconjugatesProteinuriaPublication BiasLupus NephritisAntibodies, MonoclonalLupus Erythematosus, SystemicAntirheumatic AgentsCyclophosphamideRheumatic DiseasesMycophenolic AcidAutoimmune DiseasesRheumatology
-
Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network.
Rheumatology (Oxford, England) 2024 Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, … -
Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis.
bioRxiv : the preprint server for biology 2024 Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, … -
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network.
Arthritis research & therapy 2024 Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, … -
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.
JCI insight 2024 Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta… -
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership.
Rheumatology (Oxford, England) 2022 Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, …
Show all (117 more) Hide
-
Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.
Arthritis & rheumatology (Hoboken, N.J.) 2022 Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, Belmont HM, Izmirly P, Clancy R, Trujillo JM, Fine D, Arazi A, Berthier CC, Davidson A, James JA, Diamond B, Hacohen N, Wofsy D, Raychaudhuri… -
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.
Lupus science & medicine 2021 Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery… -
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance.
Annals of the rheumatic diseases 2021 Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen… -
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Arthritis & rheumatology (Hoboken, N.J.) 2020 Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon… -
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.
Annals of the rheumatic diseases 2020 Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, … -
A Tale of Two Trials.
Arthritis & rheumatology (Hoboken, N.J.) 2020 Wofsy D -
Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis.
JCI insight 2020 Fava A, Buyon J, Mohan C, Zhang T, Belmont HM, Izmirly P, Clancy R, Trujillo JM, Fine D, Zhang Y, Magder L, Rao DA, Arazi A, Berthier CC, Davidson A, Diamond B, Hacohen N, Wofsy D, Apruzzese W, … -
The Validity of Scores From the New MCAT Exam in Predicting Student Performance: Results From a Multisite Study.
Academic medicine : journal of the Association of American Medical Colleges 2020 Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K -
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.
Arthritis care & research 2020 Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A -
The Relationships among Self-Designated Disadvantage, Socioeconomic Disadvantage, and Academic Performance in Medical School: A Multi-Institutional Study.
Journal of health care for the poor and underserved 2020 Henderson MC, Jerant A, Unkart J, Griffin EJ, Sciolla SF, Kelly CJ, Peterson EM, Hall T, Wofsy D, Fancher TL -
Georgia Abortion Law and Our Commitment to Patients.
Arthritis & rheumatology (Hoboken, N.J.) 2019 Craft JE, Crow MK, Lockshin MD, Salmon JE, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin J, Koopman WJ, Seaman WE, Wofsy D, Sergent JS, Uknis AB, Weinblatt ME -
Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis.
Nature reviews. Nephrology 2019 Rao DA, Arazi A, Wofsy D, Diamond B -
PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21.
JCI insight 2019 Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise ES, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond… -
Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.
Nature immunology 2019 Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P,… -
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Arthritis & rheumatology (Hoboken, N.J.) 2019 Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, … -
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme.
Rheumatology advances in practice 2019 Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P -
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
Annals of the rheumatic diseases 2019 Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, … -
The immune cell landscape in kidneys of patients with lupus nephritis.
Nature immunology 2019 Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P,… -
Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools.
Academic medicine : journal of the Association of American Medical Colleges 2019 Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P -
Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.
Annals of the rheumatic diseases 2019 Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, … -
Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.
Arthritis & rheumatology (Hoboken, N.J.) 2019 Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers … -
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.
The Journal of rheumatology 2018 Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, … -
Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools?
Academic medicine : journal of the Association of American Medical Colleges 2018 Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P -
Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study.
Academic medicine : journal of the Association of American Medical Colleges 2018 Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P -
Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis.
Kidney international reports 2018 Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L -
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Annals of the rheumatic diseases 2018 Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS -
Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.
Arthritis care & research 2018 Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH -
Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools.
BMC medical education 2017 Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P -
Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.
Lupus science & medicine 2017 Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D -
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
Arthritis & rheumatology (Hoboken, N.J.) 2016 Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D -
In memoriam: Ephraim P. Engleman, MD, 1911-2015.
Arthritis & rheumatology (Hoboken, N.J.) 2015 Wofsy D -
Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome.
Lupus science & medicine 2015 Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D -
Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America.
Arthritis & rheumatology (Hoboken, N.J.) 2015 Wofsy D, Diamond B, Houssiau FA -
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
Annals of the rheumatic diseases 2014 Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D -
Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.
Arthritis and rheumatism 2013 Wofsy D, Hillson JL, Diamond B -
Recent progress in conventional and biologic therapy for systemic lupus erythematosus.
Annals of the rheumatic diseases 2012 Wofsy D -
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
Arthritis and rheumatism 2012 Wofsy D, Hillson JL, Diamond B -
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
The New England journal of medicine 2011 Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, ALMS Group -
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.
The Journal of rheumatology 2011 Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE -
Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Arthritis care & research 2010 Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D -
Plagiarism on personal statements: a disturbing symptom of a broader trend.
Annals of internal medicine 2010 Papadakis MA, Wofsy D -
Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?
Nature reviews. Rheumatology 2010 Dall'Era M, Wofsy D -
Biologic therapy for systemic lupus erythematosus.
Discovery medicine 2010 Dall'Era M, Wofsy D -
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
Arthritis and rheumatism 2010 Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, ALMS Group -
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
Rheumatology (Oxford, England) 2009 Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N -
Regulatory T cells as therapeutic targets in rheumatoid arthritis.
Nature reviews. Rheumatology 2009 Esensten JH, Wofsy D, Bluestone JA -
Systemic lupus erythematosus clinical trials-an interim analysis.
Nature reviews. Rheumatology 2009 Dall'Era M, Wofsy D -
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Journal of the American Society of Nephrology : JASN 2009 Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group -
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.
JAMA 2009 Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D -
A quality indicator set for systemic lupus erythematosus.
Arthritis and rheumatism 2009 Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E, Systemic Lupus Erythematosus Quality Indicators Project Expert Panels -
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Arthritis and rheumatism 2007 Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D -
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).
Lupus 2007 Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N -
Clinical trial design in systemic lupus erythematosus.
Current opinion in rheumatology 2006 Dall'Era M, Wofsy D -
Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases.
Arthritis and rheumatism 2006 Daikh DI, Gillis J, Wofsy D -
Living in a different world.
Arthritis and rheumatism 2005 Wofsy D -
Block and tackle: CTLA4Ig takes on lupus.
Lupus 2005 Davidson A, Diamond B, Wofsy D, Daikh D -
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Arthritis and rheumatism 2002 Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group -
Treatment of autoimmune diseases by inhibition of T-cell costimulation.
Modern rheumatology 2002 Wofsy D, Daikh DI -
Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets.
Kidney international 2001 Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V -
The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G.
Immunology 1999 Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ -
Effects of anti-B7 monoclonal antibodies on humoral immune responses.
Journal of autoimmunity 1999 Daikh DI, Wofsy D -
On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases.
Transplantation proceedings 1998 Daikh DI, Wofsy D -
Opportunities for future biological therapy in SLE.
Bailliere's clinical rheumatology 1998 Wofsy D, Daikh DI -
Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
Clinical immunology and immunopathology 1998 Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D -
Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.
Journal of immunology (Baltimore, Md. : 1950) 1997 Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D -
The CD28-B7 costimulatory pathway and its role in autoimmune disease.
Journal of leukocyte biology 1997 Daikh D, Wofsy D, Imboden JB -
Blind T-cell homeostasis in CD4-deficient mice.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996 Adleman LM, Wofsy D -
Treatment of murine lupus with CTLA4Ig.
Science (New York, N.Y.) 1994 Finck BK, Linsley PS, Wofsy D -
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.
The Journal of clinical investigation 1994 Finck BK, Chan B, Wofsy D -
Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy.
Clinical immunology and immunopathology 1994 Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D -
Recent advances in the treatment of rheumatic diseases: new approaches to immunotherapy.
Ryumachi. [Rheumatism] 1994 Wofsy D -
T-cell homeostasis: implications in HIV infection .
Journal of acquired immune deficiency syndromes 1993 Adleman LM, Wofsy D -
Treatment of murine lupus with anti-CD4 monoclonal antibodies.
Immunology series 1993 Wofsy D -
The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies.
Clinical immunology and immunopathology 1992 Finck BK, Yung CM, Carteron NL, Wofsy D -
Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity.
Journal of immunology (Baltimore, Md. : 1950) 1992 Connolly K, Roubinian JR, Wofsy D -
Tumorigenesis mediated by an antigen receptor.
Proceedings of the National Academy of Sciences of the United States of America 1992 Jäck HM, Beck-Engeser G, Lee G, Wofsy D, Wabl M -
CD4 antibody therapy in systemic lupus erythematosus.
Seminars in immunology 1990 Wofsy D, Carteron NL -
F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice.
Clinical immunology and immunopathology 1990 Carteron NL, Wofsy D, Schimenti C, Ermak TH -
Regulation of immunity by anti-T-cell antibodies.
The Western journal of medicine 1990 Wofsy D -
Effects of recombinant murine tumor necrosis factor-alpha on immune function.
Journal of immunology (Baltimore, Md. : 1950) 1990 Gordon C, Wofsy D -
Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node.
Laboratory investigation; a journal of technical methods and pathology 1989 Ermak TH, Steger HJ, Wofsy D -
Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.
Clinical immunology and immunopathology 1989 Gordon C, Ranges GE, Greenspan JS, Wofsy D -
Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis.
Clinical immunology and immunopathology 1989 Erlich KS, Wofsy D, Dix RD, Mills J -
Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.
Journal of immunology (Baltimore, Md. : 1950) 1989 Carteron NL, Schimenti CL, Wofsy D -
New therapies for the rheumatic diseases.
Bulletin on the rheumatic diseases 1989 Klippel JH, Strober S, Wofsy D -
Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease.
Journal of autoimmunity 1988 Wofsy D, Chiang NY, Greenspan JS, Ermak TH -
The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus.
Journal of autoimmunity 1988 Wofsy D -
Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1988 Carteron NL, Wofsy D, Seaman WE -
Selective manipulation of the immune response in vivo by monoclonal antibodies.
Annual review of medicine 1988 Seaman WE, Wofsy D -
Treatment of autoimmune diseases with monoclonal antibodies.
Progress in allergy 1988 Wofsy D -
New approaches to treating systemic lupus erythematosus.
The Western journal of medicine 1987 Wofsy D -
Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice.
European journal of immunology 1987 Wofsy D, Chiang NY -
Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
Journal of immunology (Baltimore, Md. : 1950) 1987 Wofsy D, Seaman WE -
Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1986 Gutstein NL, Wofsy D -
Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells.
Transplantation 1986 Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE -
Induction of immune tolerance by administration of monoclonal antibody to L3T4.
Journal of immunology (Baltimore, Md. : 1950) 1986 Gutstein NL, Seaman WE, Scott JH, Wofsy D -
Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice.
Journal of immunology (Baltimore, Md. : 1950) 1986 Wofsy D -
Anti-Ly-1 antibody induces interleukin 2 release from T cells.
Journal of immunology (Baltimore, Md. : 1950) 1986 Stanton T, Stevens TL, Ledbetter JA, Wofsy D -
Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4.
Immunologic research 1986 Wofsy D, Seaman WE -
Strategies for treating autoimmune disease with monoclonal antibodies.
The Western journal of medicine 1985 Wofsy D -
Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.
Journal of immunology (Baltimore, Md. : 1950) 1985 Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P -
Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice.
Journal of immunology (Baltimore, Md. : 1950) 1985 Wofsy D, Mayes DC, Woodcock J, Seaman WE -
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
The Journal of experimental medicine 1985 Wofsy D, Seaman WE -
Treatment of murine lupus with monoclonal anti-T cell antibody.
Journal of immunology (Baltimore, Md. : 1950) 1985 Wofsy D, Ledbetter JA, Hendler PL, Seaman WE -
[Not Available].
Immunology today 1984 Wofsy D -
Hormones, handedness, and autoimmunity.
Immunology today 1984 Wofsy D -
The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens.
Journal of immunology (Baltimore, Md. : 1950) 1984 Wofsy D, Hardy RR, Seaman WE -
Monocytosis in the BXSB model for systemic lupus erythematosus.
The Journal of experimental medicine 1984 Wofsy D, Kerger CE, Seaman WE -
Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
Journal of immunology (Baltimore, Md. : 1950) 1983 Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA -
Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice.
Clinical immunology and immunopathology 1983 Shear HL, Wofsy D, Talal N -
Interleukin-2 deficiency, genes, and systemic lupus erythematosus.
Arthritis and rheumatism 1982 Talal N, Dauphinee MJ, Wofsy D -
Thymic influences on autoimmunity in MRL-lpr mice.
Scandinavian journal of immunology 1982 Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N -
Interleukin 2 deficiency is a common feature of autoimmune mice.
Journal of immunology (Baltimore, Md. : 1950) 1981 Dauphinée MJ, Kipper SB, Wofsy D, Talal N -
Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.
The Journal of experimental medicine 1981 Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N -
Interleukin-2 deficiency in murine systemic lupus erythematosus.
Transactions of the Association of American Physicians 1981 Wofsy D, Dauphinée MJ, Kipper SB, Talal N -
Culture-negative septic arthritis and bacterial endocarditis. Diagnosis by synovial biopsy.
Arthritis and rheumatism 1980 Wofsy D -
Coccidioidomycosis of the thyroid.
Annals of internal medicine 1979 Loeb JM, Livermore BM, Wofsy D